A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety po menopauzie, w wieku 18 lat lub starsze
- •Potwierdzona biopsją rak piersi w stopniu I-III, typu ER+/HER2-
- •Planowana operacja chirurgiczna jako pierwsza linia leczenia
- •Kwalifikacja do testu genetycznego zgodnie z wytycznymi National Comprehensive Cancer Network
✗ Disqualifies
- •Historia raka piersi w przeszłości
- •Otrzymanie hormonoterapii jako profilaktyka w ciągu ostatnich 3 miesięcy
- •Rak w stadium IV
- •Planowana chemioterapia przed operacją
- •Ciąża
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 2, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, United States
Trial contact
Minna Lee, MD
Komal Jhaveri, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.